LenD: a study to establish the safety and efficacy of lenalidomide and dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia?

Satyen Harish Gohil; Nicola Maciocia; Pip Patrick

首页> 外文期刊>Leukemia and lymphoma >LenD: a study to establish the safety and efficacy of lenalidomide and dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia?

【24h】

LenD: a study to establish the safety and efficacy of lenalidomide and dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia?

机译：贷款：一项研究，以确定半任业胺和地塞米松对复发或难治性慢性淋巴细胞白血病患者的安全性和疗效？

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Lenalidomide shows promise in chronic lymphocytic leukemia (CLL), mediating its anti-leukemic effect through direct cytotoxicity, modulation of the tumor microenvironment, and correction of functional defects in immune cells

机译：Lenalidomide在慢性淋巴细胞白血病（CLL）中显示出慢性淋巴细胞白血病（CLL），通过直接细胞毒性，调节肿瘤微环境调节其抗白血病效果，以及免疫细胞中功能缺陷的校正

著录项

来源
《Leukemia and lymphoma》 |2018年第8期|共4页
作者
Satyen Harish Gohil; Nicola Maciocia; Pip Patrick;
展开▼
作者单位

Department of Academic Haematology University College London Cancer Institute London UK;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. LenD: a study to establish the safety and efficacy of lenalidomide and dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia? [J] . Satyen Harish Gohil, Nicola Maciocia, Pip Patrick Leukemia and lymphoma . 2018,第7a8期

机译：贷款：一项研究，以确定半任业胺和地塞米松对复发或难治性慢性淋巴细胞白血病患者的安全性和疗效？
2. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. [J] . Chanan-Khan A, Miller KC, Musial L, Journal of Clinical Oncology . 2006,第34期

机译：来那度胺在复发或难治性慢性淋巴细胞性白血病患者中的临床疗效：II期研究的结果。
3. Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1 [J] . María-Victoria Mateos, Tamas Masszi, Norbert Grzasko, Haematologica . 2017,第10期

机译：既往治疗对口服依唑米布-来那度胺-地塞米松 vs 的疗效和安全性的影响。 TOURMALINE-MM1复发/难治性多发性骨髓瘤患者使用安慰剂来那度胺-地塞米松
4. Efficiency and Toxmcity of the Fludarabine and Cyclo- Phosphamide Combined Therapy in Relapsed/ Resistant Patients with B-cell Chronic Lymphocytic Leukaemia (CLL)-Polish Multicenter Study [C] . M. Kowal, A. Dmoszynska, D. Jawniak, European Haematology Association . 2002

机译：B-Cell慢性淋巴细胞白血病（CLL） - 渗透多中心研究的复发/抗性患者复发/抗性患者的氟氮胺碱和环磷酰胺联合治疗的效率和毒性
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1 [O] . María-Victoria Mateos, Tamas Masszi, Norbert Grzasko, 2017

机译：在TOURMALINE-MM1复发/难治性多发性骨髓瘤患者中既往治疗对口服艾达唑仑-来那度胺-地塞米松与安慰剂-来那度胺-地塞米松的疗效和安全性的影响
7. LenD: a study to establish the safety and efficacy of lenalidomide and dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia [O] . Satyen Harish Gohil, Nicola Maciocia, Pip Patrick, 2017

机译：贷款：一项研究，以确定半任业族和地塞米松对复发或难治性慢性淋巴细胞白血病患者的安全性和疗效

LenD: a study to establish the safety and efficacy of lenalidomide and dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia?

摘要

著录项

相似文献

相关主题

期刊订阅